Anything And Everything You Need To Understand About Purchasing Much Less Expensive Volasertib

Table 5 MKIs and chemotherapies received by at least 5% of sample by region for each line of treatment (n=316) Adverse events and symptoms of disease burden Similar rates of adverse events were reported for patients receiving MKIs and for those receiving chemotherapies (19.9% vs 22%), with diarrhea experienced most commonly for those receiving MKIs (11.2%), and nausea and vomiting most commonly noted for those receiving chemotherapies (12.6%) (Table 6). Table 6 Adverse events among patients ever treated with MKIs (n=206) and chemotherapies (n=127) Symptoms as a result of disease burden were examined by disease state (data not shown). Patients SERCA who experienced disease progression in response to treatment (regardless of type) were more likely to report trouble breathing (51.6% vs 12.9%) and bone pain (48.4% vs 22.4%) than those with objective tumor response (both P-values Luminespib with patients reporting one disease symptom, patients reporting two or more symptoms had a greater mean number of visits to the treating physician in the prior 12 months (9.37 vs 7.00, P=0.001). Additionally, patients with two or more symptoms also had a greater mean number of physician visits including outside providers, than those with one symptom (12.87 vs 8.96, PVolasertib molecular weight shown). Those who were on second through fourth lines had a greater mean doctor visits with the current physician than those on first line (11.07 vs 7.44, P